Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The Transaction was announced by the Company through a press release on 5 June 2025. Both companies remain fully committed to the strategic rationale for the reverse takeover and intend to complete the Transaction. However, in light of Nasdaq Stockholm AB's ("Nasdaq") current position, that it will not approve the contemplated "Red Chip" structure for the Transaction, Qlife and Hipro acknowledge that the process may take longer than originally anticipated. While alternative structures are being evaluated, the companies will in the short term focus on deepening their collaboration and accelerating the business and operational synergies already identified by entering into an exclusive commercial agreement. The exclusivity of the non-binding Letter of Intent has been extended, and the Transaction remains conditional upon, inter alia, the signing of a share purchase agreement no later than 31 December 2026. Both parties intend to continue their joint value creation for the benefit of both companies. The parties have agreed that the valuation term in the non-binding Letter of Intent will be re-evaluated once a revised transaction structure has been established.